Century Therapeutics (NASDAQ:IPSC) Posts Quarterly Earnings Results

Century Therapeutics (NASDAQ:IPSC) posted its quarterly earnings results on Tuesday. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.08, RTT News reports. The company had revenue of $0.79 million during the quarter, compared to the consensus estimate of $0.47 million. Century Therapeutics had a negative return on equity of 60.60% and a negative net margin of 6,434.23%. During the same quarter in the prior year, the company earned ($0.55) EPS.

Century Therapeutics Stock Up 5.0 %

Shares of IPSC stock traded up $0.07 on Thursday, reaching $1.46. The company’s stock had a trading volume of 653,856 shares, compared to its average volume of 261,578. The company has a market capitalization of $123.69 million, a P/E ratio of -0.79 and a beta of 1.41. Century Therapeutics has a 12-month low of $1.14 and a 12-month high of $5.51. The stock’s 50 day simple moving average is $1.52 and its 200-day simple moving average is $2.24.

Wall Street Analyst Weigh In

Several research firms recently commented on IPSC. Chardan Capital cut their price objective on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a report on Thursday. HC Wainwright decreased their price objective on Century Therapeutics from $9.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Rodman & Renshaw began coverage on Century Therapeutics in a research note on Thursday, August 8th. They issued a “buy” rating and a $6.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Century Therapeutics has an average rating of “Buy” and an average price target of $11.60.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.